omniture
上海药明生物技术有限公司 Wuxi Biologics

Latest News

WuXi Biologics Reports Solid 2023 Annual Results

Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross Profit Rose by 1.5% to RMB6,827.9 Mi...

2024-03-26 21:53 950

WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment

SHANGHAI, March 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Con...

2024-03-05 21:00 1151

WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics

* Named Top-Rated for fourth consecutive year * Committed to generating long-term value for all ...

2024-02-21 18:00 2494

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

-  First manufacturing run successful for MFG7 facility at the Ireland site -  Largest manufacturing...

2024-01-31 17:31 2088

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

-  WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy ...

2024-01-25 08:30 1258

WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

SHANGHAI, Jan. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Con...

2024-01-17 08:30 3726

WuXi Biologics to Increase Manufacturing Capacity in Massachusetts

* The added capacity will further enhance WuXi Biologics' commercial manufacturing capabilities i...

2024-01-08 17:52 4009

WuXi Biologics Named to 2023 Dow Jones Sustainability World Index

* Identified as a global sustainability leader by S&P Global * Committed to generating long-term...

2023-12-12 17:00 2137

WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating

* Ranked in top 1% of the over 100,000 companies evaluated * Recognized for outstanding performa...

2023-12-08 17:40 3503

WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale

* By leveraging WuXiUPTM, WuXi Biologics has completed its first end-to-end continuous drug subst...

2023-11-22 13:21 3280

WuXi Biologics Receives AAA MSCI ESG Rating

SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Cont...

2023-11-08 08:30 1270

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

* WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibilit...

2023-10-17 08:30 1274

WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease

WUXI, China, Oct. 1, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global C...

2023-10-02 08:30 1150

WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services

SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Con...

2023-08-11 08:30 4077

WuXi Biologics to Increase Manufacturing Capacity in Germany

-  In response to global clients' increasing demand for contract manufacturing services, WuXi Biolo...

2023-06-01 16:49 3170

WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations

DUNDALK, Ireland, May 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading gl...

2023-05-22 16:30 2200

WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

* WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-cl...

2023-05-16 16:00 1775

WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability

* The Report outlines new goals of net-zero GHG emissions across all operations by 2050 and a 10%...

2023-04-28 14:43 2669

WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease

WUXI, China, March 28, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global...

2023-03-28 20:11 1869

WuXi Biologics Reports Remarkable 2022 Annual Results

Revenue Increased by 48.4% Y-o-Y to RMB15,268.7 Million Gross Profit Increased by 39.2% Y-o-Y to R...

2023-03-22 20:09 2827